Cargando…

Drug-induced liver injury in COVID-19 patients during hospitalization

Since coronavirus disease 2019 (COVID-19) outbreaks in December 2019 in Wuhan, almost no studies have systematically described drug-induced liver injury (DILI) in COVID-19 patients. This study aimed to assess the characteristics of liver test abnormality or liver injury in patients with COVID-19, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ying, Shi, Cai, Zhan, Haiyan, Yang, Boning, Liu, Jun, Rong, Peipei, Luo, Yi, Yang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018522/
https://www.ncbi.nlm.nih.gov/pubmed/36930097
http://dx.doi.org/10.1097/MD.0000000000033294
_version_ 1784907827559530496
author Chen, Ying
Shi, Cai
Zhan, Haiyan
Yang, Boning
Liu, Jun
Rong, Peipei
Luo, Yi
Yang, Jian
author_facet Chen, Ying
Shi, Cai
Zhan, Haiyan
Yang, Boning
Liu, Jun
Rong, Peipei
Luo, Yi
Yang, Jian
author_sort Chen, Ying
collection PubMed
description Since coronavirus disease 2019 (COVID-19) outbreaks in December 2019 in Wuhan, almost no studies have systematically described drug-induced liver injury (DILI) in COVID-19 patients. This study aimed to assess the characteristics of liver test abnormality or liver injury in patients with COVID-19, and further to explore DILI in COVID-19 patients during hospitalization. It was a single-center retrospective analysis of confirmed severe acute respiratory syndrome coronavirus 2 infected patients in the hospital from January 2020 to March 2020. Univariate and multivariate logistic regression analysis were used to assess the risk factors associated with liver test abnormality or liver injury. At admission, 148 (48.8%, 148/303) patients had abnormal liver test results and 7 (2.4%, 7/303) had liver injury, while 195 (64.4%, 195/303) had abnormal liver test results and 17 (5.6%, 17/303) had liver injury during hospitalization. After excluding these patients with liver disease and liver function abnormalities or liver injury at admission, 15 (11.1%, 15/135) patients developed DILI during hospitalization. Further regression analysis indicated that methylprednisolone (odds ratio = 4.177, 95% confidence interval [1.106–15.771], P = .035), but not Chinese herbal medicine or other used drug, was associated with DILI in patients during hospitalization. Abnormal liver function results were in more than half of patients with COVID-19, and the incidence of DILI in COVID-19 patients was 11.1% during hospitalization. Liver test abnormality or liver injury in patients might be directly caused by the viral infection at admission, but the detrimental effects on liver injury mainly related to certain medications used during hospitalization, particularly methylprednisolone. Severe COVID-19 could increase the occurrence of liver injury (P = .007) during hospitalization, but not a risk factor of liver injury. However, Chinese herbal medicine was a protective factor for liver injury.
format Online
Article
Text
id pubmed-10018522
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-100185222023-03-17 Drug-induced liver injury in COVID-19 patients during hospitalization Chen, Ying Shi, Cai Zhan, Haiyan Yang, Boning Liu, Jun Rong, Peipei Luo, Yi Yang, Jian Medicine (Baltimore) 4200 Since coronavirus disease 2019 (COVID-19) outbreaks in December 2019 in Wuhan, almost no studies have systematically described drug-induced liver injury (DILI) in COVID-19 patients. This study aimed to assess the characteristics of liver test abnormality or liver injury in patients with COVID-19, and further to explore DILI in COVID-19 patients during hospitalization. It was a single-center retrospective analysis of confirmed severe acute respiratory syndrome coronavirus 2 infected patients in the hospital from January 2020 to March 2020. Univariate and multivariate logistic regression analysis were used to assess the risk factors associated with liver test abnormality or liver injury. At admission, 148 (48.8%, 148/303) patients had abnormal liver test results and 7 (2.4%, 7/303) had liver injury, while 195 (64.4%, 195/303) had abnormal liver test results and 17 (5.6%, 17/303) had liver injury during hospitalization. After excluding these patients with liver disease and liver function abnormalities or liver injury at admission, 15 (11.1%, 15/135) patients developed DILI during hospitalization. Further regression analysis indicated that methylprednisolone (odds ratio = 4.177, 95% confidence interval [1.106–15.771], P = .035), but not Chinese herbal medicine or other used drug, was associated with DILI in patients during hospitalization. Abnormal liver function results were in more than half of patients with COVID-19, and the incidence of DILI in COVID-19 patients was 11.1% during hospitalization. Liver test abnormality or liver injury in patients might be directly caused by the viral infection at admission, but the detrimental effects on liver injury mainly related to certain medications used during hospitalization, particularly methylprednisolone. Severe COVID-19 could increase the occurrence of liver injury (P = .007) during hospitalization, but not a risk factor of liver injury. However, Chinese herbal medicine was a protective factor for liver injury. Lippincott Williams & Wilkins 2023-03-17 /pmc/articles/PMC10018522/ /pubmed/36930097 http://dx.doi.org/10.1097/MD.0000000000033294 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 4200
Chen, Ying
Shi, Cai
Zhan, Haiyan
Yang, Boning
Liu, Jun
Rong, Peipei
Luo, Yi
Yang, Jian
Drug-induced liver injury in COVID-19 patients during hospitalization
title Drug-induced liver injury in COVID-19 patients during hospitalization
title_full Drug-induced liver injury in COVID-19 patients during hospitalization
title_fullStr Drug-induced liver injury in COVID-19 patients during hospitalization
title_full_unstemmed Drug-induced liver injury in COVID-19 patients during hospitalization
title_short Drug-induced liver injury in COVID-19 patients during hospitalization
title_sort drug-induced liver injury in covid-19 patients during hospitalization
topic 4200
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018522/
https://www.ncbi.nlm.nih.gov/pubmed/36930097
http://dx.doi.org/10.1097/MD.0000000000033294
work_keys_str_mv AT chenying druginducedliverinjuryincovid19patientsduringhospitalization
AT shicai druginducedliverinjuryincovid19patientsduringhospitalization
AT zhanhaiyan druginducedliverinjuryincovid19patientsduringhospitalization
AT yangboning druginducedliverinjuryincovid19patientsduringhospitalization
AT liujun druginducedliverinjuryincovid19patientsduringhospitalization
AT rongpeipei druginducedliverinjuryincovid19patientsduringhospitalization
AT luoyi druginducedliverinjuryincovid19patientsduringhospitalization
AT yangjian druginducedliverinjuryincovid19patientsduringhospitalization